Navidea Biopharma (NAVB) Moves Higher as Insiders Buy Back In
Tweet
Share
E-mailGet Alerts NAVB Hot Sheet
Join SI Premium – FREE
Navidea Biopharmaceuticals (Nasdaq: NAVB) is higher on the session Friday amid a mix of insider buying recently.
Disclosing purchases made 12th are:
Notably, the pharma was issued a CRL from the FDA on September 10th for Lymphoseek. Shares are down over 20 percent for the week, but up about 6 percent today.
Disclosing purchases made 12th are:
- Director Brendan Ford - on September 12th for 5,000 shares and total cost of $13,200;
- Director Gordon Troup bought 5,000 on August 15th and 5,000 on September 12th. The cost was $31,080;
- CEO Mark J. Pykett acquired 4,000 on September 11th. Gross cost of $10,552; and
- Business Chief Tom Tulip bought 15,000 shares at $2.70 for gross cost of $40,500 on September 14th.
Notably, the pharma was issued a CRL from the FDA on September 10th for Lymphoseek. Shares are down over 20 percent for the week, but up about 6 percent today.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Angel founders transfer 10M+ super-voting shares to mission trust
- Wellgistics Health executives exercise warrants for 200,000 shares
- Situational Awareness LP discloses 10% stake in SharonAI Holdings
Create E-mail Alert Related Categories
Insider Trades, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
